09:52 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three-month period ended March 31, 2022. Unless otherwise noted, all amounts are in U.S. dollars. Total revenue in the quarter was $0.8 million compared to negative $6.0 million in the first quarter of 2021, The Company incurred a net loss of $7.0 million, or $(0.00) per share, for the quarter compared to a loss of $12.8 million, or $(0.01) per share, in the first quarter of 2021. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $4.40.
